[Systemic retinoid therapy with etretinate in pachyonychia congenita].
On the basis of two case-reports it is concluded that the aromatic derivative of retinoic acid, etretinate, is a promising drug in the treatment of pachyonychia congenita.
Hoting
E
E
Wassilew
S W
SW
D000284:Administration, Oral; D000328:Adult; D005050:Etretinate / Q000627:therapeutic use*; D006801:Humans; D007645:Keratoderma, Palmoplantar / Q000188:drug therapy / Q000235:genetics*; D007972:Leukoplakia, Oral / Q000188:drug therapy / Q000235:genetics*; D008048:Lip Neoplasms / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged
D005050:Etretinate
Systemische Retinoidtherapie mit Etretinat bei Pachyonychia congenita.